In this single-group phase-2 trial, patients pre-treated (previous platinum-based therapy and/or anti-PDL1 therapy) for KRAS G12C mutant lung cancer received second-/third-line sotorasib, with a primary endpoint of objective response (OR). The gene discussed is KRAS; the disease is lung cancer.